NCT05547061View on ClinicalTrials.gov

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Prostate CancermCRPC
Interventions
DRUG

Lu-177-DGUL

Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

DRUG

Ga-68-NGUL

Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.

Trial Locations (4)

Unknown

Chonnam National University Hwasun Hospital, Hwasun

Asan Medical Center, Seoul

Seoul National University Bundang Hospital, Seoul

03127

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Cellbion Co., Ltd.

INDUSTRY

NCT05547061 - A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | Biotech Hunter | Biotech Hunter